Recursion Pharmaceuticals has raised $60 million to step up its artificial intelligence-enabled drug discovery activities. The series B equips Recursion to move beyond its initial focus on repurposing ...
Bayer plans to wield Recursion’s drug discovery platform—combining artificial intelligence with automated, “wet lab” biology experiments—to comb through its libraries of potential small molecule ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results